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Aeginetia indica Linn. (Guan-Jen-Huang, GJH), a traditional Chinese herb, has the potential to be an immunomodulatory agent.
The purpose of this study was to explore the eﬀect of GJH in the treatment of renal cancer. Concentration-eﬀect curves for the
inﬂuence of GJH on cellular proliferation showed a biphasic shape. Besides, GJH had a synergistic eﬀect on cytotoxicity when
combined with 5-ﬂuorouracil (5-FU)which may be due to the alternation of the chemotherapeutic agent resistance-related genes
and due to the synergistic eﬀects on apoptosis. In addition, treatment with GJH extract markedly reduced 786-O cell adherence to
human umbilical vein endothelial cells (HUVECs) and decreased 786-O cell migration and invasion. In a xenograft animal model,
GJH extract had an inhibitory eﬀect on tumor cell-induced metastasis. Moreover, western blot analysis showed that the expression
of intercellular adhesion molecule-1 (ICAM-1) in 786-O cells was signiﬁcantly decreased by treatment with GJH extract through
inactivation of nuclear factor-κB( N F – κB). These results suggest that GJH extract has a synergistic eﬀect on apoptosis induced
by chemotherapeutic agents and an inhibitory eﬀect on cell adhesion, migration, and invasion, providing evidence for the use of
water-based extracts of GJH as novel alternative therapeutic agents in the treatment of human renal cancer.
1.Introduction
Renal cell carcinoma (RCC) is the most common solid lesion
found within the kidney and accounts for approximately
90% of renal malignancies [1]. Despite improvements in
diagnostic techniques and treatment strategies, currently
there is no evidence that the use of targeted therapies,
alone or in combination with adjuvant treatments, treats
localized RCC and improves overall survival. However, 4
largerandomizedadjuvantclinicaltrialsareongoingandwill
address the feasibility and eﬃcacy of treatment in localized
RCC [2, 3]. In addition, currently licensed target agents
are cost-ineﬀe c t i v ea n dh a v eal o to fc o m m o ns i d ee ﬀects.
Therefore, a more potent alternative agent is required to
achieve acceptable clinical and oncological outcomes.
Metastasis, a common feature of RCC, is a multistep
process that leads to the development of secondary tumors.
Preventingtheoccurrenceofanyofthesestepswouldprevent
metastasis[4].Duringthemetastaticcascade,primarytumor
cells digest their surrounding extracellular matrix, migrate
through interstitial spaces, and enter the blood or lymphatic
vessels where they are carried to distant organs [5]. The
adhesion of circulating tumor cells to the microvascular
endothelium of organs at distant sites is an important step
in metastasis. Once lodged in the target organs, these cells
migrate into the interstitial spaces and continue to grow and
develop a secondary tumor, or they metastasize [6]. Thus,
the adhesion, migration, and invasion of cancer cells provide
many potential targets for therapeutic intervention.
Increasing evidence suggests that some medicinal herbs
may decrease the risk of malignancies. Studies have shown
that phytochemicals contained within herbs are promising
chemopreventive agents. Aeginetia indica Linn. (Chinese
name “Guan-Jen-Huang”, GJH), a root parasitic plant, has2 Evidence-Based Complementary and Alternative Medicine
been used as folk medicine in Taiwan and other countries
to treat chronic liver diseases, cough, and arthritis. The seed
extract of GJH induces potent antitumor immunity [7–9].
This formula is used as health food even today, and several
studies have demonstrated the antitumor eﬀect of a 55-kDa
protein isolated from the seed of GJH [8, 10–12]. However,
the eﬀects of GJH herbal extract in human cancers remain to
be determined.
In the present study, we report that a water-based extract
of GJH inhibits tumor growth and metastasis. The treatment
of 786-O renal carcinoma cells with GJH resulted in a syn-
ergistic eﬀect on 5-ﬂuorouracil (5-FU)-induced apoptosis,
inhibition of cell migration and invasion, and reduction in
cell adherence to endothelial cells. The molecular mecha-
nisms involved in these eﬀects include the downregulation
of chemotherapeutic agent resistance-related genes and
intercellular adhesion molecule-1 (ICAM-1) expression, in
parallel with the reduction of nuclear factor-κB( N F - κB)
expression and activation.
2.MaterialsandMethods
2.1. Plant Extracts. GJH plants were approved and extracted
by Sun Ten Pharmaceutical Company (Taipei, Taiwan).
In brief, dry plant materials were ﬁnely ground, and the
extracts were prepared by boiling 250g of plant material in
1250mL of water for 30min. The extracts were concentrated
to 250mL with an evaporator at room temperature. The
extract was then centrifuged at 3000rpm for 10min and
ﬁltered through a 0.45-mm syringe ﬁlter. Stock solutions at a
concentration of 1g/mL were stored at −20◦C until use.
2.2. Cell Lines. The RCC cell line 786-O was obtained
from the American Type Culture Collection and maintained
in RPMI 1640 (Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Invitrogen), 2mM l-glutamine (Invit-
rogen), and 100μg/mL penicillin-streptomycin (Invitrogen).
Human umbilical vein endothelial cells (HUVECs) were
obtained from the Bioresource Collection and Research
Center and maintained in medium 199 (Invitrogen) sup-
plemented with 20% FBS, 25U/mL heparin (Sigma), and
30μg/mL ECGS (Sigma). All cells were maintained in a
humidiﬁed atmosphere of 5% CO2 at 37◦C.
2.3. Cell Proliferation Assay. 786-O cells were seeded in 96-
well plates in serum-reduced medium (1% FBS) containing
various concentrations of GJH (0–100mg/mL) at a density
of 2 × 104 cells/mL per well for 24h. To investigate the
combined eﬀect of GJH and anticancer drugs, 786-O cells
were seeded in 96-well plates at 5 × 103 cells/mL per well
and incubated for 24h. On the following day, 100μL aliquots
containing GJH and/or the anticancer drugs 5-FU, cisplatin,
or paclitaxel (all from Sigma) were added to each well and
the cells were cultured for a further 48h. The number of
viable cells was estimated by measuring the conversion of the
tetrazolium salt MTT to formazan crystals. After incubation
with MTT for 4h, formazan crystals were solubilized with
DMSO and quantiﬁed spectrophotometrically by measuring
the absorbance at 590nm with a reference wavelength of
650nm.
2.4. Combination Index Analysis. The combined eﬀects of
GJH and anticancer drugs were quantiﬁed using a combi-
nation index (CI) method developed by Chou and Talalay
[13]. This method involves plotting dose-eﬀect curves for
each agent and their combination, using the median-eﬀect
equation: fa/fu = (D/Dm)m, where D is the dose of the
drug, Dm is the dose required for a 50% cytotoxic eﬀect
(equivalenttoCC50),faandfuaretheaﬀectedandunaﬀected
fractions (fa = 1 − fu), respectively, and m is the exponent
signifying the sigmoidicity of the dose-eﬀect curve. The
relative concentrations of GJH and the anticancer drugs,
determined as (concentration)/(CC50 value), were used for
analysis.ThevaluesofDmandmwerecalculatedﬁrst.TheCI
used for analysis of the drug combinations was determined
by the equation for mutually nonexclusive drugs that have
diﬀerent modes of action: CI = (D)1/(Dx)1 + (D)2/(Dx)2 +
(D)1(D)2/(Dx)1(Dx)2, where (D)1 and (D)2 are relative
concentrations of drugs 1 and 2, and x is the percentage
of inhibition. Combination indices CI < 1, CI = 1a n d
CI > 1 indicate synergistic, additive, and antagonistic eﬀects,
respectively.
2.5. Annexin V-Binding Assay. 786-O cells were seeded at
a density of 1.0 × 106 cells/well and incubated with the
indicated doses of GJH, 5-FU, GJH + 5-FU, or 3% H2O2
(as a positive control) for 48h. Cells were then collected
by centrifugation (1000×g for 5min), washed twice with
Annexin V-binding buﬀer (PBS containing 2.5mM CaCl2),
and resuspended in the same buﬀer. After that, 200μL
of the cell suspension was incubated with 5μL of biotin-
conjugated Annexin V (biotin-Annexin V; Biovision) for
5min at room temperature in the dark. The cells were
then washed twice with Annexin V-binding buﬀer and ﬁxed
in 200μL of 2% formaldehyde in PBS for 15min. After
washing twice with PBS, the ﬁxed cells were incubated
with horseradish peroxidase (HRP)-conjugated streptavidin
(eBioscience) for 30min at room temperature. The biotin-
Annexin V bound to phosphoserine (PSer) exposed on
the cell surface was detected spectrophotometrically using
the HRP substrate 3,3 ,5,5 -tetramethylbenzidine (TMB;
eBioscience), by measuring the absorbance at 450nm with
a reference wavelength of 650nm.
2.6. Real-Time Quantitative RT-PCR. Total RNA was
extracted using TRIzol reagent (Invitrogen) in accordance
with the manufacturer’s instructions and further digested
with DNase I (Promega). The integrity of the RNA was
conﬁrmed before quantitative (q) RT-PCR analysis. Then,
1μgofRNAwasreversetranscribedinthepresenceofSuper-
Script II RT (Invitrogen) and oligo(dT) primers (Invitrogen)
at 42◦C for 1h followed by incubation at 70◦Cf o r1 5m i n
to inactivate the enzymes. Ampliﬁcation of the cDNA was
performed using SYBR Green PCR Master Mix (ABgene)
and analyzed with the iCycler iQ Real-Time PCR Detection
System (Bio-Rad). Primers were designed by the Beacon
Designer 4 program (Premier Biosoft International) andEvidence-Based Complementary and Alternative Medicine 3
sequences are listed in Table 1. The PCR conditions com-
prised an initial denaturation at 95◦C for 15min, followed
by 40 cycles at 95◦C for 10s and 60◦C for 45s. A dissociation
procedure was performed to generate a melting curve for
conﬁrmationoftheampliﬁcationspeciﬁcity.Theresultswere
normalized to glyceraldehyde 3-phosphate dehydrogenase.
T h er e l a t i v el e v e l so fg e n ee x p r e s s i o na r er e p r e s e n t e da s
−ΔCt = (Ctgene −Ctreference), and the fold change in gene
expression was calculated by the 2(−ΔΔCt) method (where
Ct is cycle threshold) as described previously [14].
2.7. Antibodies and Western Blotting. Antibodies against
intact or cleaved forms of of poly (ADP-ribose) polymerase
(PARP), β-catenin, cyclin D1, and ICAM-1 were obtained
from Cell Signaling Technology. Antibodies against NF-κB
p65 and p50 subunits and Sp-1 were purchased from Santa
Cruz Biotechnology. A primary antibody against total actin
and goat anti-mouse and goat anti-rabbit HRP secondary
antibodies were from Chemicon. Total cell lysates extracted
with lysis buﬀer (50mM Tris-HCl [pH 8.0], 150mM NaCl,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
[SDS], and 1% NP-40) containing a protease inhibitor
cocktail, or nuclear fraction extracted using the NE-PER
Nuclear Protein Extraction Kit (Thermo Scientiﬁc), were
analyzed. The protein concentration was determined using
a BCA protein assay kit (Thermo Scientiﬁc). Proteins were
separated by 10% SDS-polyacrylamide gel electrophoresis
and transferred to a polyvinylidene ﬂuoride membrane
(Immobilon-P, 0.45mm; Millipore, Billerica, MA, USA)
using NA-1512 Semi-Dry Transfer apparatus (NIHON
EIDO). The membranes were blocked with 5% skim milk in
Tris-buﬀered saline containing 1% Tween 20 (TBST, pH 7.4)
at room temperature for 30min and incubated overnight at
4◦C with primary antibody. The membranes were washed
4 times with TBST for 10min each at room temperature
and incubated with HRP-conjugated secondary antibody
for 1h at room temperature. The membranes were then
washed 4 times with TBST. Proteins were visualized using
an enhanced chemiluminescence (ECL) kit and western
blotting detection reagents (GE Healthcare Life Sciences)
and exposed to X-ray ﬁlm (Fuji, Tokyo, Japan). Each band
was quantitatively determined using the Image J program
(http://rsb.info.nih.gov/). The densitometry readings of the
bands were normalized to actin expression.
2.8. Cell Motility Assay. 786-O cells were left untreated
or treated with 2.5 or 5.0mg/mL of GJH for 24h at
37◦C, seeded in a 6-well plate, and grown overnight to
conﬂuency in serum-containing medium. The conﬂuent cell
layer was scratched with a p200 Eppendorf pipette tip. After
24h, the closure of the scratch wound was photographed
at 400x magniﬁcation under a phase contrast microscope
(Olympus).
2.9. Cell Invasion Assay. 786-O cells (1 × 105 cells) were
resuspended in 300μL medium containing 1% FBS with
various concentrations of GJH and were then seeded into
Transwell inserts (8μm pore; Millipore) precoated with
Table 1: Oligonucleotide sequences used in real-time qRT-PCR.
Gene Oligonucleotide sequence
ERCC1 5 -GGGAATTTGGCGACGTAATTC-3 
5 -GCGGAGGCTGAGGAACAG-3 
TUBB3 5 -GCGAGATGTACGAAGACGAC-3 
5 -TTTAGACACTGCTGGCTTCG-3 
Tau 5 -TGACACGGACGCTGGCCTGAA-3 
5 -CACTTGGAGGTCACCTTGCTC-3 
TS1 5 -GGCCTCGGTGTGCCTTT-3 
5 -GATGTGCGCAATCATGTACGT-3 
GAPDH 5 -TCAACGACCACTTTGTCAAGCT-3 
5 -GTGAGGGTCTCTCTCTTCCTCTTGT-3 
growth factor-reduced Matrigel (1μg/mL; BD Biosciences).
Complete medium was added to the lower chamber. After
incubation for 24h, invasive cells were ﬁxed, stained, and
quantiﬁed in 3 random ﬁelds (100x magniﬁcation) per
insert.
2.10.Cell-CellAdhesionAssay. HUVECs wereseededonto6-
well plates and left to grow for 48h before experiments. 786-
O cells were treated with GJH (1.3–5.0mg/mL) in serum-
reduced medium (1% FBS) for 6h and then labeled with
the ﬂuorescent dye BCECF/AM (Sigma) at 37◦C for 30min.
The ﬂuorescence-labeled 786-O cells were pelleted and
resuspended (3 × 104 cells) in medium 199 with 10mM N-
2-hydroxyethylpiperazine-N -2-ethanesulfonic acid buﬀer
(M199H) and added onto the HUVECs layer. After 30min,
cell suspensions were discarded and the adhered labeled
786-O cells were gently washed with M199H. The number
of labeled cells was measured using SigmaGel 1.0 (Jandel
Scientiﬁc). Analyses were repeated 3 times over the same
region, and the results presented are the mean values of 3
independent experiments.
2.11. Animal Experiments. All animal experiments were
conducted according to the regulations approved by the
Institutional Animal Care and Use Committee of the College
of Medicine, National Taiwan University. Female nonobese
diabetic/severe combined immunodeﬁcient mice (6–8 weeks
old) were obtained from the Animal Center of National
Taiwan University. 786-O cells (1×106 cells) were suspended
in 200μL of growth factor-reduced medium and inoculated
intravenously into the tail vein of mice weighing 20 to
25g (n = 10). Two days after injection, the mice were
orally administered either water or GJH (25g/kg) daily and
weighed every other day (n = 5 for each group). After oral
administration of GJH for 30 days, the mice were sacriﬁced
and their lungs were excised and weighed to estimate tumor
content.
2.12. Electrophoretic Mobility Shift Assay (EMSA). 786-O
cells in serum-reduced medium (1% FBS) were treated with
GJH(1.3–5.0mg/mL)for6h.Nuclearextractswereprepared
using the NE-PER Nuclear Protein Extraction Kit (Thermo4 Evidence-Based Complementary and Alternative Medicine
Scientiﬁc). Detection of NF-κBw a sp e r f o r m e dw i t ha
biotin-labeled oligo probe containing the proximal NF-κB
recognitionsite,whichspanstheregionofthehumanICAM-
1p r o m o t e r :5  -GGGAGCCCGGGGAGGATTCCT-3  [15].
For competition experiments, excess cold oligonucleotide
probe (2-fold excess and 4-fold excess without biotin label,
presented as 2 × URE and 4 × URE, resp.) was added 15min
before addition of the labeled probe. Supershift assays were
performed with 1μg of the antibody against p65 incubated
for 30min at 4◦C after addition of the probe. The reaction
products were analyzed via 5% nondenaturing polyacry-
lamide gel electrophoresis using 12.5mM Tris, 12.5mM
boric acid, and 0.25mM EDTA (pH 8.3), for 4-5h at 280–
300V/10–12mA. The gels were transferred and blocked
as described above. After incubating at room temperature
for 1h with HRP-conjugated streptavidin (eBioscience), the
membranes were washed and visualized as described above.
2.13. Luciferase Reporter Assay. At o t a lo f1×105 786-O cells
were plated in a 6-well plate for 24h. Following transfection
with 0.1μgo faN F - κB-responsive luciferase reporter for
6h, the cultures were replated into a 96-well plate at a
density of 2 × 104 cells/mL per well. The cells were grown
in standard medium for another 18h followed by treatment
with GJH alone or in combination with TNF-α for 6h.
Luciferase activity was measured using a Luciferase Assay Kit
(Stratagene) according to the manufacturer’s instructions,
using a luminometer (Berthold LB960) and an integration
period of 60s.
2.14. Statistical Analysis. The Image J program (http://rsb
.info.nih.gov/) was used for quantization of the expression
fold in western blot or EMSA analyses. The fold increase
of the indicated proteins was determined by normalizing to
actin or Sp1 when they could be detected. SPSS 12.0 for
Windows (SPSS Inc.) was used to analyze all data. A two-
tailed paired-samples Student’s t-test was used for statistical
analysis of comparative data from 2 groups. A P value <0.05
was considered statistically signiﬁcant.
3. Results
3.1. Eﬀect of GJH on the Growth of 786-O Renal Carcinoma
Cells. To evaluate the eﬀect of GJH on renal cancer cells
in vitro, 786-O renal carcinoma cells were exposed to
1–100mg/mL of GJH for 24h. Cell viability was then
determined by MTT assay. After 24h of treatment, low
doses (1.0, 3.0, and 10.0mg/mL) of GJH increased 786-O
cell proliferation, whereas high doses (>10mg/mL) caused
a decrease in 786-O proliferation (Figure 1). Among the
concentrations tested, 3.0mg/mL GJH was the most eﬀective
in stimulating 786-O cell proliferation. The growth of 786-
O cells decreased in a dose-dependent manner. The value
of the 50% cytotoxic concentration (CC50)f o r2 4 ho f
treatment was determined to be 35 ± 0.5mg/mL. These
ﬁndings indicate that low concentrations of GJH induce the
proliferation of 786-O cells, while high doses of GJH are
cytotoxic for 786-O cells.
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Figure 1: Biphasic eﬀects of GJH on cell viability in 786-O cells.
Cells were incubated with GJH (1–100mg/mL) for 24h. The
viability of cells was determined by MTT assay. Low concentra-
tions (1–10mg/mL) of GJH increase whereas high concentrations
(>10mg/mL) repress cell proliferation. The mean (SD) is shown
from at least 3 separate experiments. ∗∗∗P<0.001.
3.2.EﬀectsofGJHSupplementationontheAnticancerActionof
5-FU In Vitro. To explore the potentially useful combination
of GJH with chemotherapeutic agents commonly used in
renal cancer therapy, we assessed the interaction between
GJH and several chemotherapeutic agents in 786-O cells.
The synergistic analysis indicated that GJH had a synergistic
eﬀect on the cytotoxicity of 5-FU in a relatively broad
dose inhibition range (30–75% fraction aﬀected in 786-O
cells; Figures 2(a) and 2(b)), while no synergistic interaction
between GJH and cisplatin or paclitaxel was observed (data
notshown).Biotin-AnnexinVbindingwasdetectedintarget
cells as an index for the translocation of PSer from the inner
to the outer monolayer of the cell surface membrane (ﬂip-
ﬂop) that happens during the early stages of apoptosis. The
3% H2O2 treated group showed a relatively high intensity
of binding (absorbance, ∼1.3 at 450nm) that served as
a positive control. As shown in Figure 2(c), the negative
control (PBS treatment) showed ∼3.3% of the apoptotic
response seen in the 3% H2O2 group. Although GJH (at
12.5% and 25% cytotoxic concentration, CC12.5 and CC25,
resp.) slightly enhanced apoptotic responses (5.2% and 6.5%
of the H2O2 group, resp.), the combination of GJH and 5-FU
(CC12.5 or CC25 for both treatments) induced signiﬁcantly
stronger apoptotic responses (18.7% and 32.1% of the H2O2
group, resp.) when compared to 5-FU alone (CC12.5 and
CC25 were 8.55% and 19.4%, resp. of the H2O2 group).
We also investigated the inﬂuence of GJH on chemother-
apeutic agent-associated gene expression. GJH in combina-
tion with 5-FU could signiﬁcantly suppress the expression
levels of chemotherapeutic agent resistance-related genes in
786-O cells. Real-time quantitative RT-PCR showed that
GJH signiﬁcantly enhances the alternation of chemothera-
peutic agent resistance-related genes: upregulation of exci-
sion repair cross-complementing gene 1 (ERCC1) andEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Synergistic eﬀect between GJH and 5-FU on 786-O cancer cell apoptosis. (a) A dose-response survival curve for GJH and the
chemotherapeutic agent 5-FU in 786-O cells. (b) CI values at diﬀerent levels of growth inhibition eﬀect (fa). (c) GJH (CC12.5 and CC25)
enhances the apoptotic response to 5-FU (CC12.5 and CC25, resp.) as demonstrated by Annexin V-binding assay. (d) Combination treatment
with GJH and 5-FU upregulates the expression of ERCC1 but downregulates the expression of TUBB3, Tau, and TS1 as shown by real-time
quantitative RT-PCR. (e) Western blot analysis indicates that GJH (CC25) enhances the 5-FU (CC25)-induced cleavage of PARP, as well as
5-FU-induced reduction in expression of β-catenin and cyclin D1. The mean (SD) is shown from at least 3 separate experiments.6 Evidence-Based Complementary and Alternative Medicine
downregulation of thymidylate synthase 1 (TS), class III β-
tubulin (TUBB3), and microtubule-associated protein tau
(Tau), respectively, (CC25 o fG J H+C C 25 of 5-FU was more
eﬀective than either CC25 of GJH or CC25 of 5-FU alone;
Figure 2(d)). In addition, westernblot analysisindicated that
GJH enhanced 5-FU-induced cleavage of PARP, as well as 5-
FU-induced reduction in expression of β-catenin and cyclin
D1 (CC25 of GJH + CC25of 5-FU was more eﬀective than
either CC25 of GJH or CC25 of 5-FU alone; Figure 2(e)).
These results indicate that a useful synergistic interaction
exists between GJH and 5-FU in 786-O renal cancer cells.
Possible mechanisms for this synergy may include the alter-
nation of chemotherapeutic agent resistance-related genes
and synergistic eﬀects on apoptosis.
3.3. Antimetastatic Eﬀect of GJH in 786-O Cells In Vitro and
In Vivo . Cell adhesion and migration are important factors
to consider when investigating the metastatic potential of
cancer cells. Adhesion to extracellular matrices is considered
to be a pivotal step in the invasive process of metastatic
cells. To investigate the potential eﬀect of GJH on metastasis,
we ﬁrst examined the adhesion of 786-O cells to conﬂuent
monolayers of HUVECs in 6-well plates after exposure of
the cells to GJH for 6h. A signiﬁcant reduction in adhesion
was observed in GJH (1.3–5.0mg/mL)-treated cells when
compared with the control cells (69.7% reduction after
5.0mg/mL GJH treatment; Figure 3(a); P<0.001). The
inhibition of 786-O cell migration was examined using
a wound healing assay, and the results are shown in
Figure 3(b). Phase-contrast images were taken at 6 and 12h.
Longer (12h) incubation with GJH (2.5 and 5.0mg/mL)
led to greater inhibition of cell migration in 786-O cells. A
Matrigelinvasionassaywasperformedtodeterminetheanti-
invasiveeﬀectofGJHin786-Ocells.After24hofincubation,
GJH (1.3–5.0mg/mL)-treated cells showed a decreased level
of invasion compared to control cells (83.7% reduction after
5.0mg/mL GJH treatment; Figure 3(c); P<0.01).
TheeﬀectsofGJHoncellmetastasiswerethenexamined.
Animal experiments showed that oral administration of GJH
(25g/kg per day) signiﬁcantly reduced metastatic tumor
nodules in the lungs during a 30-day follow-up period
(542.0 ± 124.5mg versus 243.0 ± 52.6mg in control group
a n dG J Ht r e a t e dg r o u p ,r e s p . ;Figure 3(d); P<0.01). In
addition, the dosage used in vivo did not have any signiﬁcant
toxic eﬀects and did not signiﬁcantly alter body weight
during the 30-day experimentation period (79.6 ± 8.1%
versus94.9 ±11.3%incontrolgroupandGJHtreatedgroup,
resp.; Figure 3(e); P>0.05). Taken together, these results
support the idea that GJH inhibits renal cancer metastasis in
vitro and in vivo.
3.4. Downregulation of ICAM-1 Expression and Reduction in
NF-κB Transcriptional Activity Are Involved in GJH-Mediated
Anticancer Eﬀects. It is known that cancer cell-endothelial
cell interactions are regulated in part by the expression
of speciﬁc adhesion molecules on the cell surface, such as
ICAM-1.Therefore,theexpressionofICAM-1wasexamined
in GJH-treated and untreated cells. Western blot analysis
indicated that GJH signiﬁcantly reduces the expression
of ICAM-1 in both dose- and time-dependent manners
(Figure 4(a)). Since aberrant regulation of the transcription
factor NF-κB and its signaling pathways are involved in can-
cer development and progression [16, 17], and the induction
of ICAM-1 involves activation of NF-κB, the eﬀects of GJH
on NF-κBw e r ee x a m i n e d .W h o l ec e l ll y s a t e so rn u c l e a r
extracts of 786-O cells with or without GJH treatment were
prepared,andtheexpressionandthenucleartranslocationof
NF-κB protein were analyzed. Western blot analysis showed
that the amounts of p65 and p50 NF-κB subunits in the
nuclear fraction were signiﬁcantly reduced in both whole
cell lysate and nuclear fraction of 786-O cells after GJH
treatment(Figure 4(b)).Meanwhile,byinvestigatingtheNF-
κB binding activity to the ICAM-1 promoter, EMSA analysis
showed that the DNA-binding activity of NF-κB to the
ICAM-1 promoter was decreased by GJH treatment (50.1%
reduction after 5.0mg/mL GJH treatment; Figure 4(c)). To
quantify binding activity, a luciferase reporter containing the
NF-κB binding region was introduced into 786-O cells. NF-
κB-induced luciferase activity was reduced by 61.8%, 79.8%,
and94.1%aftertreatmentwith1.3,2.5,and5.0mg/mLGJH,
respectively, (Figure 4(d), black bar). TNF-α (10ng/mL)
increasedtheactivityofNF-κBby2.77-fold;thiswasreduced
by 58.1%, 76.8%, and 82.5% by 1.3, 2.5, and 5.0mg/mL
GJH, respectively, (Figure 4(d), white bar). It is known that
TNF-α playsa role in the induction of ICAM-1expression via
activation of NF-κB. Therefore, these results imply that GJH
downregulates TNF-α-dependent and TNF-α-independent
ICAM-1 expression, in part by reducing the expression and
inactivating the transcriptional activity of NF-κB.
4. Discussion
Although many anticancer drugs are used clinically, they
generally induce strong cellular cytotoxicity and related
side eﬀects. A cancer drug with little or no toxicity to
normal cells is required. Many studies have shown that
GJH has a variety of therapeutic eﬀects [7–12]. However,
the eﬀects of water-based extracts of GJH in human can-
cers have not been determined. In the present study, we
explored the anticancer eﬀects of a water-based extract of
GJH. The molecular mechanisms of GJH action involve
the downregulation of chemotherapeutic agent resistance-
related genes and ICAM-1 expression, in parallel with the
reduction of NF-κB expression and activation in 786-O renal
carcinoma cells. This results in a synergistic eﬀect on 5-
FU-induced apoptosis, inhibition of cancer cell migration
and invasion, and adherence of cancer cells to HUVECs.
To the best of our knowledge, the present study is the ﬁrst
to demonstrate the therapeutic potential of GJH in human
renal carcinoma. According to the compatibility of Chinese
herbal medicine, GJH belongs to a monarch formula, which
may need an assistant or a guide formulas to form a
prescription. The potential clinical applications of GJH may
include enhancement of drug targeting as well as decreased
side eﬀects in renal cancer patients.
The adhesion molecule ICAM-1 plays an important
role in the regulation of cellular inﬂammatory responses
[8] and transduces several intracellular signal transductionEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: Antimetastatic eﬀect of GJH on 786-O cells. GJH (1.3–5.0mg/mL) signiﬁcantly reduced the (a) adhesion of 786-O cells to
HUVECs, the (b) migration and (c) invasion of 786-O cells. (d) Animal experiments showed that oral administration of GJH (25g/kg
per day for a total of 30 days) signiﬁcantly reduces metastatic tumor nodules in the lungs as demonstrated by lung weight. (e) There was
no signiﬁcant diﬀerence in body weight between mice treated with (open circle) and without (closed circle) GJH. The mean (SD) is shown
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Figure 4: GJH downregulates the expression of ICAM-1 through reduction of the expression and transcriptional activity of NF-κB. (a) GJH
signiﬁcantly reduces the expression of ICAM-1 in both dose- and time-dependent manners, as shown by western blot analysis. (b) Western
blotting reveals that GJH reduces the amounts and the nuclear translocation of NF-κB p65 and p50 subunits in the cells. (c) GJH reduces the
DNA-binding activity of NF-κB to ICAM-1 as shown by EMSA analysis. (d) GJH downregulates TNF-α-dependent and TNF-α-independent
ICAM-1 expression in part through NF-κB as demonstrated by the luciferase reporter assay. The mean (SD) is shown from at least 3 separate
experiments. ∗∗∗P<0.001.
pathways. Its expression is activated by immunotherapeutic
agents such as TNF-α, alone or in combination with
other interleukins, in patients with renal cancer [18–25].
The present study shows that GJH can reduce cancer cell
motility in vitro and in vivo. In addition, the inhibition
of oncogenic functions including the adhesion of cancer
cells to endothelial cells, cell migration, and cell invasion by
GJH occurred concurrently with the reduction of ICAM-
1 expression. This indicates that ICAM-1 expression may
be of functional importance in cancer cell adhesion and
motility. Our preliminary data indicated that a high content
of apigenin was detected in the water-based extract of
GJH (Figure 1 of Supplementary Material available at doi:
10.1155/2012/935860), and in GJH-induced cytoskeleton
rearrangement through downregulation of Rac 1 expression
(Figure 2 of Supplementary Material). These results suggest
that apigenin may be one of the major active anticancer
components of GJH. Although the detailed contents of GJH
and their molecular mechanisms need to be investigated
further, these results provide information related to the
ability of GJH extracts to arrest cell motility in renal cancer
cells, supporting its potential to inhibit metastatic renal
tumors.
On the other hand, the death and growth of cells are
balanced by the opposing processes of cellular apoptosis
and proliferation, respectively, under normal conditions.
Inhibition of uncontrolled cell proliferation and/or enhance-
ment of cellular apoptosis may help to maintain normal
cellular homeostasis and decrease the chances of neoplastic
progression. Our results demonstrate a biphasic eﬀect of
GJH on the growth of cultured human renal cancer cells
and only showed signiﬁcant inhibition of growth at higher
concentrations. Some phytochemicals, such as curcumin
and apigenin, also show biphasic eﬀects in cultured cells;Evidence-Based Complementary and Alternative Medicine 9
low concentrations stimulate cell proliferation, whereas high
concentrations are cytotoxic [26, 27]. One reason for this
may be the involvement of distinct kinases or growth factors
at diﬀerent concentrations of GJH. Although the reason for
this diﬀerential eﬀect of GJH on renal cancer cells remains
to be determined, the current study evaluated the synergistic
eﬀect of GJH in combination with 5-FU, but not cisplatin
and paclitaxel, in apoptosis. Similarly to the way that the
importance of food synergy (the perspective of evaluating
whole foods rather than single food components) has been
clariﬁed [28, 29], the synergistic eﬀect supports the use of
GJH in combination with 5-FU during cancer therapy.
In conclusion, the present study shows that GJH has a
synergistic eﬀect on 5-FU-mediated apoptosis and inhibits
cell adhesion and motility. The results of this study support
the potential of GJH as a useful chemotherapeutic agent for
thetreatmentofrenalcancer.Itsclinicalapplicationwarrants
further investigations into the molecular mechanisms and
beneﬁcial eﬀects of GJH.
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